Announcement: COVID-19 impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcing the launch of In Review
In partnership with Research Square, Molecular Autism is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
A community-based participatory research model has found that autistic mothers face unique challenges compared to their non-autistic counterparts, including higher rates of post-partum depression.
Autistic mothers could benefit from increased understanding and acceptance among individuals who interact them.
Call for Papers - Open Collections
Simon Baron-Cohen, University of Cambridge, UK
Joseph Buxbaum, Icahn School of Medicine at Mount Sinai, New York
Molecular Autism is a peer-reviewed, open access journal that publishes high-quality basic, translational and clinical research that has relevance to the etiology, pathobiology, or treatment of autism and related neurodevelopmental conditions. Research that includes integration across levels is encouraged. Molecular Autism publishes empirical studies, reviews, and brief communications.
We encourage submissions from a range of fields including (but not restricted to) genetics, molecular neurobiology, neuropathology, neuroimaging, cognitive neuroscience, epidemiology, and biomarker discovery. Molecular Autism also publishes articles on screening, diagnosis and classification, including articles that consider subgrouping to refine our understanding of basic mechanisms. Intervention studies are also welcome, especially when considered with respect to revealing causal mechanisms.
Joseph Buxbaum, co-Editor-in-Chief
Joseph Buxbaum is a molecular geneticist and neuroscientist, Director of the Seaver Autism Center for Research and Treatment, and Professor at the Icahn School of Medicine at Mount Sinai. Dr Buxbaum is the founder and co-lead investigator of the Autism Sequencing Consortium, an international collaboration to discover genes for autism. He has also been elected to the prestigious National Academy of Medicine (NAM), in recognition of his important contributions to uncovering the genetic and molecular basis of autism.
Simon Baron-Cohen, co-Editor-in-Chief
Simon Baron-Cohen is Professor of Developmental Psychopathology at the University of Cambridge and Fellow at Trinity College, Cambridge. He is also Director of the Autism Research Centre (ARC) in Cambridge and Director of CLASS (Cambridge Lifespan Asperger Syndrome Service), a clinic for adults with suspected AS.
Annual Journal Metrics
79 days to first decision for reviewed manuscripts only
56 days to first decision for all manuscripts
175 days from submission to acceptance
34 days from acceptance to publication
1,963 Altmetric mentions